Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials.

Author: Bujas-BobanovicM, JonesP H, KaralisD G, LeiterL A, LetierceA, MandelJ, SamuelR, TinahonesF J

Paper Details 
Original Abstract of the Article :
AIM: To evaluate the safety of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab according to diabetes mellitus status. METHODS: Safety data from 14 trials (8-104-week durations) were analysed by treatment (alirocumab or placebo/ezetimibe control) and diabetes status (y...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585811/

データ提供:米国国立医学図書館(NLM)

A Look at Alirocumab Safety: Diabetes and Beyond

The world of medicine is constantly evolving, and the field of [cardiology] is no exception. This study dives deep into the safety of [alirocumab], a drug used to manage [high cholesterol]. It utilizes a [pooled data analysis] approach, combining information from 14 trials, to provide a comprehensive picture of its effects. The researchers were particularly interested in understanding how [diabetes mellitus status] might influence the safety profile of this medication.

Diabetes: A Factor in Injection Site Reactions?

One of the key findings of this study is the correlation between [diabetes mellitus] and the occurrence of [local injection site reactions] after receiving [alirocumab]. While [alirocumab] was generally safe for both individuals with and without diabetes, those with diabetes experienced fewer injection site reactions compared to their counterparts. This observation suggests that [diabetes mellitus] might have a moderating effect on this particular side effect.

Navigating the Landscape of Safety

The study also sheds light on the broader safety profile of [alirocumab] in individuals with [diabetes mellitus]. Despite the observed differences in injection site reactions, the overall safety of [alirocumab] was found to be similar across both groups. This finding is reassuring for patients with [diabetes mellitus] who might be considering this medication as a treatment option.

Dr.Camel's Conclusion

This research, like a desert oasis offering respite from the harsh realities, provides valuable insights into the safety of [alirocumab] in individuals with and without [diabetes mellitus]. It reminds us that even within the vast landscape of medical research, understanding the nuances of patient characteristics is crucial. The study's findings are a reminder that while [alirocumab] is generally safe, individual factors, such as [diabetes mellitus status], may influence specific side effects. This research highlights the importance of individualised care and the need for tailored medical approaches.

Date :
  1. Date Completed 2019-04-16
  2. Date Revised 2023-10-12
Further Info :

Pubmed ID

30183102

DOI: Digital Object Identifier

PMC6585811

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.